IGFL1 Inhibitors
Chemicals categorized as IGFL1 Inhibitors largely fall into two primary categories: signaling pathway inhibitors and kinase inhibitors. The signaling pathway inhibitors, such as IGF-1R Inhibitor and Rapamycin, target the receptor level or downstream elements of the IGF signaling cascade, a pathway with which IGFL1 can interact. These inhibitors are highly specific in their mode of action, interfering with receptor activation or phosphorylation events. This targeted disruption the transduction of signals that IGFL1 relies on for its function, rendering it less effective in exerting its cellular influence.
The second category, kinase inhibitors like PD98059, Trametinib, and SP600125, target a variety of kinases implicated in different pathways. Kinases serve as critical regulatory points in signaling pathways and are responsible for the phosphorylation of downstream targets. Because IGFL1 is known to modulate some of these pathways, inhibiting key kinases can result in a disturbance in the signaling cascades that IGFL1 interacts with. For example, Trametinib inhibits MEK, a component of the MAPK pathway, which can interact with IGFL1. By inhibiting these kinases, these compounds obstruct the function of IGFL1 indirectly, by altering the cellular pathways that it may regulate.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Splitomicin | 5690-03-9 | sc-358701 | 5 mg | $48.00 | ||
This inhibitor directly targets the IGF-1 receptor, which is a part of the IGF signaling pathway, a pathway IGFL1 can potentially interact with. It prevents the receptor's phosphorylation, thus attenuating IGFL1 signaling. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
This EGFR inhibitor can affect pathways that have crosstalk with IGFL1-mediated processes. By inhibiting EGFR, WZ4002 reduces cellular events that IGFL1 could influence. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
As a PI3K inhibitor, LY294002 interferes with the PI3K/Akt pathway. Considering that IGFL1 can modulate this pathway, inhibition of PI3K would obstruct IGFL1's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This mTOR inhibitor blocks a key node in the IGF signaling pathway. As IGFL1 can operate in the same pathway, Rapamycin serves as an indirect inhibitor. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
By inhibiting the MEK1/2 kinases, PD98059 disrupts the ERK signaling pathway, which IGFL1 may interact with to induce cellular responses. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
This MEK inhibitor would obstruct the MAPK pathway, which IGFL1 could be affecting. This compound, therefore, acts as an indirect inhibitor of IGFL1. | ||||||
cFMS Receptor Tyrosine Kinase Inhibitor | 870483-87-7 | sc-203877 sc-203877A | 1 mg 5 mg | $32.00 $54.00 | ||
This c-FMS inhibitor can interrupt the function of macrophages, which may be affected by IGFL1. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
This BCR-ABL inhibitor can disrupt various signaling pathways that IGFL1 may interface with, serving as an indirect inhibitor. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
This proteasome inhibitor can affect protein degradation, thereby altering the turnover of IGFL1 or its interacting proteins. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
As a Rho-associated protein kinase (ROCK) inhibitor, Y-27632 can affect cellular processes like apoptosis and migration, processes that IGFL1 could modulate. | ||||||